{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:51Z","timestamp":1793137011177,"version":"4.5.0"},"reference-count":32,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T00:00:00Z","timestamp":1640131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/13696998.2021.2011301","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T10:40:58Z","timestamp":1639564858000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5937-0936","authenticated-orcid":false,"given":"Jipan","family":"Xie","sequence":"first","affiliation":[{"name":"Analysis Group, Inc., Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9326-0148","authenticated-orcid":false,"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Xu","sequence":"additional","affiliation":[{"name":"MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, Brisbane, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer T.","family":"Fine","sequence":"additional","affiliation":[{"name":"MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, Brisbane, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3738-2973","authenticated-orcid":false,"given":"Jenny","family":"Lam","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Brisbane, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9468-4989","authenticated-orcid":false,"given":"Louis P.","family":"Garrison","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,12,22]]},"reference":[{"issue":"25","key":"e_1_3_4_2_1","first-page":"e558","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen SR","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, et\u00a0al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142(25):e558\u2013e631.","journal-title":". Circulation"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311059"},{"key":"e_1_3_4_4_1","volume-title":"Hypertrophic cardiomyopathy overview. GeneReviews\u00ae","author":"Cirino AL","year":"2021","unstructured":"Cirino AL, Ho C. Hypertrophic cardiomyopathy overview. GeneReviews\u00ae. [Internet]: Seattle (WA): University of Washington; 2021."},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.644682"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1710575"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.78.2.182"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-016-0467-x"},{"issue":"1","key":"e_1_3_4_9_1","first-page":"34","article-title":"Quality of life in outpatients with hypertrophic cardiomyopathy","volume":"9","author":"Jacquelinet M","year":"2017","unstructured":"Jacquelinet M, Pentiah AD, Coisne A, et\u00a0al. Quality of life in outpatients with hypertrophic cardiomyopathy. Arch Cardiovasc Dis Suppl. 2017;9(1):34.","journal-title":"Arch Cardiovasc Dis Suppl"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-012-0182-y"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051330"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00763-7"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-13"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.5603\/KP.a2018.0033"},{"key":"e_1_3_4_16_1","unstructured":"Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims [Internet] 2009. [cited August 06 2021]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.012"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.02.009"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00531-3"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.4.5.581"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199685219.001.0001"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-019-0095-3"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.10.066"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12363"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcab014"},{"key":"e_1_3_4_28_1","volume-title":"NICE DSU technical support document 8: an introduction to the measurement and valuation of health for NICE submissions. Report by the decision support unit","author":"Brazier J","year":"2011","unstructured":"Brazier J, Longworth L. NICE DSU technical support document 8: an introduction to the measurement and valuation of health for NICE submissions. Report by the decision support unit. London: National Institute for Health and Care Excellence (NICE); 2011."},{"key":"#cr-split#-e_1_3_4_29_1.1","unstructured":"Institute for Clinical and Economic Review (ICER). 2020-2023. Value Assessment Framework [Internet]. 2020 Jan 21 [updated 2021 Oct 25"},{"key":"#cr-split#-e_1_3_4_29_1.2","unstructured":"cited 2021 Nov 11]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2021\/10\/ICER_2020_2023_VAF_102521.pdf"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2018-000932"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0471-x"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00425.x"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2021.2011301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:24:57Z","timestamp":1729164297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2021.2011301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,22]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/13696998.2021.2011301"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2021.2011301","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}